Characteristics of Subjects With Overweight or Obesity at the Onset of Hypertension

Overview

The study aims to investigate the characteristics of subjects with hypertension at onset among a cohort of apparently healthy subjects, with overweight or obesity (BMI ≥ 25 Kg / m2), and free of any drug treatment at the baseline. The evaluation includes anthropometric (weight, height, BMI, waist circumference), haematochemical (hormones, metabolic and routine) parameters and the screening for hypertension with ABPM. The diagnosis of hypertension is made in accordance with the 2017 guidelines of the American College of Cardiology / American Heart Association ACC / AHA.

Study Type

  • Study Type: Observational
  • Study Design
    • Time Perspective: Prospective
  • Study Primary Completion Date: October 1, 2020

Interventions

  • Other: Observational study
    • Observational and prospective study

Clinical Trial Outcome Measures

Primary Measures

  • Insulin
    • Time Frame: At baseline
    • Insulin (mIU/L) concentration in serum
  • Potassium
    • Time Frame: At baseline
    • Potassium (mmol/L) concentration in serum
  • Sodium
    • Time Frame: At baseline
    • Sodium (mEq/L) concentration in serum
  • eGFR (estimated glomerular filtration rate)
    • Time Frame: At baseline
    • eGFR (ml/min/1.73 mq)
  • Creatinin
    • Time Frame: At baseline
    • Creatinin (mg/dl) concentration in serum
  • Uric acid
    • Time Frame: At baseline
    • Uric acid (mg/dL) concentration in serum
  • Total cholesterol
    • Time Frame: At baseline
    • Total cholesterol (mg/dL) concentrations in serum
  • Thyroid hormones (FT3, FT4)
    • Time Frame: At baseline
    • FT3 (pg/mL), FT4 (pg/mL) concentration in serum
  • HDL cholesterol
    • Time Frame: At baseline
    • HDL cholesterol (mg/dL) concentrations in serum
  • LDL cholesterol
    • Time Frame: At baseline
    • LDL cholesterol (mg/dL) concentrations in serum
  • Triglycerides
    • Time Frame: At baseline
    • Triglycerides (mg/dL) concentrations in serum
  • TSH
    • Time Frame: At baseline
    • TSH (mU/L) concentration in serum

Secondary Measures

  • BMI
    • Time Frame: At baseline
    • BMI (kg/m^2)
  • Height
    • Time Frame: At baseline
    • Height in meters
  • Weight
    • Time Frame: At baseline
    • Weight in kilograms

Participating in This Clinical Trial

Inclusion Criteria

  • Overweight or obesity (BMI> 25 Kg/m2) Exclusion Criteria:

  • Any kind of drug – Hypertension – Endocrine diseases (diabetes mellitus, hypo or hyperthyroidism, hypopituitarism, etc.), – Chronic inflammatory diseases – Renal failure – Liver failure – Angina pectoris – Myocardial infarction and heart failure – Genetic heart diseases – Thrombocytopenias

Gender Eligibility: All

Minimum Age: 35 Years

Maximum Age: 55 Years

Are Healthy Volunteers Accepted: Accepts Healthy Volunteers

Investigator Details

  • Lead Sponsor
    • Azienda Ospedaliera Specializzata in Gastroenterologia Saverio de Bellis
  • Provider of Information About this Clinical Study
    • Principal Investigator: Gianluigi Giannelli, Clinical Professor – Azienda Ospedaliera Specializzata in Gastroenterologia Saverio de Bellis

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.